Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Tetsu Yamamoto, Ryoji Hyakudomi, Kiyoe Takai, Kazunari Ishitobi, Yuki Uchida, Yoshitsugu Tajima
Summary: The study evaluated the feasibility, safety, and efficacy of postoperative adjuvant chemotherapy with docetaxel/cisplatin/S-1 (DCS) in patients with stage III gastric cancer after curative gastrectomy. Results showed that DCS regimen was acceptable with significant efficacy, indicating it as an effective postoperative treatment option for stage III gastric cancer patients.
Article
Oncology
Tsuneo Shimokawa, Kazuhiko Yamada, Hiroshi Tanaka, Kaoru Kubota, Yuichi Takiguchi, Kazuma Kishi, Haruhiro Saito, Yukio Hosomi, Terufumi Kato, Daijiro Harada, Sakiko Otani, Takashi Kasai, Yoichi Nakamura, Toshihiro Misumi, Takeharu Yamanaka, Hiroaki Okamoto
Summary: Cisplatin-based chemoradiotherapy is standard treatment for locally advanced non-small-cell lung cancer. This study compared SP (S-1 and cisplatin) and DP (docetaxel and cisplatin) regimens, finding that SP had higher 2-year survival rates and fewer toxicities. SP may be considered as a reference regimen in the future.
Article
Oncology
Yukinori Kurokawa, Jin Matsuyama, Kazuhiro Nishikawa, Atsushi Takeno, Yutaka Kimura, Kazumasa Fujitani, Ryohei Kawabata, Yoichi Makari, Tetsuji Terazawa, Hisato Kawakami, Daisuke Sakai, Toshio Shimokawa, Taroh Satoh
Summary: In this study comparing the efficacy and toxicities of docetaxel plus S-1 (DS) and cisplatin plus S-1 (CS) regimens for AGC without measurable lesions, DS showed slightly but non-significantly less toxicity and higher efficacy in terms of overall survival compared to CS.
Article
Oncology
Kensei Yamaguchi, Keiko Minashi, Daisuke Sakai, Tomohiro Nishina, Yasushi Omuro, Masahiro Tsuda, Shiroh Iwagami, Hisato Kawakami, Taito Esaki, Naotoshi Sugimoto, Takashi Oshima, Ken Kato, Kenji Amagai, Hisashi Hosaka, Keigo Komine, Hisateru Yasui, Yuji Negoro, Kenji Ishido, Takahiro Tsushima, Shirong Han, Shinichi Shiratori, Tomoko Takami, Kohei Shitara
Summary: The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy drugs S-1 and oxaliplatin or cisplatin for advanced gastric/gastroesophageal junction cancer. The results showed favorable efficacy and safety in patients with PD-L1-positive, HER2-negative tumors.
Article
Oncology
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
Summary: In patients with metastatic or recurrent gastric cancer, the S-1/oxaliplatin (SOX) regimen showed non-inferiority to the S-1 plus cisplatin (SP) regimen in terms of progression-free survival, with similar overall survival and different toxicity profiles between the two regimens.
Article
Oncology
Arlene E. Garcia-Soto, Nathalie D. McKenzie, Margaret E. Whicker, Joseph M. Pearson, Edward A. Jimenez, Lorraine Portelance, Jennifer J. Hu, Joseph A. Lucci, Rehman Qureshi, Andrew Kossenkov, Lauren Schwartz, Gordon B. Mills, Amit Maity, Lilie L. Lin, Fiona Simpkins
Summary: The study showed that Nelfinavir sensitized cervical cancer cells to radiation, leading to increased apoptosis and tumor suppression in vivo. The combination of NFV with concurrent CRT was well tolerated and showed promising response rates in patients with locally advanced cervical cancer, warranting further investigation.
Article
Oncology
Xi-Lei Zhou, Chang-Hua Yu, Wan-Wei Wang, Fu-Zhi Ji, Yao-Zu Xiong, Wei-Guo Zhu, Yu-Suo Tong
Summary: In locally advanced ESCC patients, CCRT with S-1 has lower incidence of severe adverse events compared to CCRT with docetaxel and cisplatin. However, elderly patients in the DP group had a significantly higher rate of severe adverse events compared to younger patients. There were no significant differences in overall response rate and 3-year survival rate between the two groups.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Kazuya Takamochi, Masahiro Tsuboi, Morihito Okada, Seiji Niho, Satoshi Ishikura, Shunsuke Oyamada, Takuhiro Yamaguchi, Kenji Suzuki
Summary: This study investigated the use of concurrent chemoradiotherapy followed by surgery for stage IIIA (N2) lung squamous cell carcinoma (LSCC). The results showed promising outcomes, with high 2-year progression-free survival and overall survival rates. The study suggests that this treatment approach is feasible for LSCC patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki
Summary: This study aims to evaluate the efficacy and safety of consolidation therapy with durvalumab following the SP regimen in Japanese patients with LA-NSCLC, with a focus on PFS and OS. The SP regimen is expected to have lower incidences of adverse effects and higher success rates in transitioning to durvalumab after chemoradiotherapy, potentially leading to improved outcomes.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Jia Wei, Xiaofeng Lu, Qin Liu, Lin Li, Song Liu, Fangcen Liu, Yao Fu, Xiangshan Fan, Yang Yang, Chuang Qi, Yangyang Yu, Wenxian Guan, Baorui Liu
Summary: The combination of PD-1 blockade and chemoradiotherapy as neoadjuvant therapy shows promising results in patients with unresectable locally advanced gastric cancer, with acceptable side effects.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Kohei Kasahara, Chikara Kunisaki, Sho Sato, Hiroki Kondo, Masazumi Takahashi, Yuko Tamura, Nobuhiro Tsuchiya, Yusaku Tanaka, Kei Sato, Jun Kimura, Takashi Kosaka, Hidetaka Ono, Hirochika Makino, Hirotoshi Akiyama, Itaru Endo
Summary: This study aimed to evaluate the long-term outcomes of neoadjuvant chemotherapy using the DCS regimen in stage III gastric cancer patients. The results showed that the 5-year RFS and OS rates were 69.8% and 74.3%, respectively. Immune-nutritional status before and after NAC significantly affected the long-term survival of patients.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Takashi Yoshioka, Masanobu Takahashi, Yasuhiro Sakamoto, Akira Okita, Tadahisa Fukui, Yasuko Murakawa, Yoshiaki Shindo, Hiroo Imai, Hisatsugu Ohori, Hidekazu Shirota, Natsuko Chiba, Yuriko Ito Sasahara, Takashi Nomura, Norimasa Fukushima, Takuhiro Yamaguchi, Hideki Shimodaira, Chikashi Ishioka
Summary: This study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1. The results showed that this treatment regimen is not suitable for gastric cancer.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Andrew J. Sinnamon, Michelle Savoldy, Rutika Mehta, Sean P. Dineen, Luis R. Pena, Gregory Y. Lauwers, Jose M. Pimiento
Summary: This study aimed to examine the prognostic value of the current NCCN definition of TRG in LRGC. The results showed that TRG0 is rare but has a good prognosis, while the pathologic lymph node status is the strongest prognostic factor.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Chemistry, Medicinal
Xiaotong Chen, Fangcen Liu, Xiaoxiao Yu, Lin Li, Jiayao Yan, Xinjie Chen, Qin Liu, Baorui Liu
Summary: Gastric cancer is a global health problem and its treatment is limited by off-target side effects. Peptide-drug conjugates (PDCs) offer a targeted drug delivery strategy to overcome drug resistance and improve antitumor effects. In this study, we proposed KK-LC-1 as a potential target for PDC design and reported the first KK-LC-1-targeting PDC product 1131-MMAE. 1131-MMAE efficiently entered KK-LC-1 positive gastric cancer cells, released the drug, and arrested the cell cycle. As a monotherapy, 1131-MMAE significantly delayed tumor growth with reduced toxicity. Furthermore, we demonstrated that 1131-MMAE was a potent radiosensitizer, enhancing the radiation response of KK-LC-1 positive tumor cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)